Literature DB >> 17198740

The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.

Bettina Burnworth1, Susanne Arendt, Sonja Muffler, Volker Steinkraus, Eva B Bröcker, Catalina Birek, Wolfgang Hartschuh, Anna Jauch, Petra Boukamp.   

Abstract

As proposed by Hanahan and Weinberg (2000. Cell 100, 57-70) carcinogenesis requires crucial events such as (i) genomic instability, (ii) cell cycle deregulation, (iii) induction of a telomere length maintenance mechanism, and (iv) an angiogenic switch. By comparing the expression of p53, cyclin D1, p16, hTERT, and TSP-1 in spontaneously regressing keratoacanthoma (KA) as a paradigm of early neoplasia, with malignant invasive cutaneous squamous cell carcinoma (SCC) as a paradigm of advanced tumour development, we are now able to assign the changes in the expression of these proteins to specific stages and allocate them to defined roles in the multi-step process of skin carcinogenesis. We show that mutational inactivation of the p53 gene, and with that the onset of genomic instability is the earliest event. Individual p53-positive cells are already seen in "normal" skin, and 3/5 actinic keratoses (AKs), 5/22 KAs, and 13/23 SCCs contain p53-positive patches. Cell cycle deregulation was indicated by the overexpression of the cell cycle regulator cyclin D1, as well as by the loss of the cell cycle inhibitor p16. Interestingly, overexpression of cyclin D1 - observed in 80% of KAs and SCCs, respectively - showed a cell cycle-independent function in HaCaT cell transplants on nude mice. Cyclin D1 overexpression was associated with a massive inflammatory response, finally leading to tissue destruction. Loss of the cell cycle inhibitor p16, on the other hand, correlated with SCCs. Thus, it is tempting to suggest that overexpression of cyclin D1 is an early change that in addition to growth stimulation leads to an altered epithelial-mesenchymal interaction, while functional p16 is able to control this deregulated growth and needs to be eliminated for malignant progression. Another requirement for uncontrolled growth is the inhibition of telomere erosion by up-regulating telomerase activity. As measured by hTERT protein expression, all of the KAs and SCCs studied were positive, with a similar distribution of the protein in both groups and an expression pattern resembling that of normal epidermis. Thus, telomerase may not need to be increased significantly in skin carcinomas. Finally, we show that the angiogenesis inhibitor TSP-1 is strongly expressed in most KAs, and mainly by the tumour cells, while in SCCs the generally weak expression is restricted to the tumour-stroma. Furthermore, we provide evidence that the loss of a copy of chromosome 15 is responsible for reduced TSP-1 expression and thereby this aberration contributes to tumour vascularisation (i.e. the angiogenic switch) required for malignant growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198740     DOI: 10.1016/j.ejcb.2006.11.002

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  12 in total

Review 1.  Epigenetic cancer prevention mechanisms in skin cancer.

Authors:  Kamalika Saha; Thomas J Hornyak; Richard L Eckert
Journal:  AAPS J       Date:  2013-08-01       Impact factor: 4.009

2.  α-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1.

Authors:  Mark R Silvis; Bridget T Kreger; Wen-Hui Lien; Olga Klezovitch; G Marianna Rudakova; Fernando D Camargo; Dan M Lantz; John T Seykora; Valeri Vasioukhin
Journal:  Sci Signal       Date:  2011-05-24       Impact factor: 8.192

Review 3.  From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma.

Authors:  Vladimir Ratushny; Michael D Gober; Ryan Hick; Todd W Ridky; John T Seykora
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  The DNA damage-binding protein XPC is a frequent target for inactivation in squamous cell carcinomas.

Authors:  Sebastien de Feraudy; Katie Ridd; Lauren M Richards; Pui-Yan Kwok; Ingrid Revet; Dennis Oh; Luzviminda Feeney; James E Cleaver
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

5.  Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.

Authors:  A Mizrahi; A Barzilai; D Gur-Wahnon; I Z Ben-Dov; S Glassberg; T Meningher; E Elharar; M Masalha; J Jacob-Hirsch; H Tabibian-Keissar; I Barshack; J Roszik; R Leibowitz-Amit; Y Sidi; D Avni
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

6.  CHREBP suppresses gastric cancer progression via the cyclin D1-Rb-E2F1 pathway.

Authors:  Jianming Zhang; Jing Zhang; Zhongmao Fu; Yuan Zhang; Zai Luo; Pengshan Zhang; Yitian Xu; Chen Huang
Journal:  Cell Death Discov       Date:  2022-06-29

7.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

8.  Chronic inflammation-related DNA damage response: a driving force of gastric cardia carcinogenesis.

Authors:  Runhua Lin; Dejun Xiao; Yi Guo; Dongping Tian; Hailong Yun; Donglin Chen; Min Su
Journal:  Oncotarget       Date:  2015-02-20

9.  Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.

Authors:  Kevin N Woodward
Journal:  ISRN Vet Sci       Date:  2011-04-12

10.  MoKCa database--mutations of kinases in cancer.

Authors:  Christopher J Richardson; Qiong Gao; Costas Mitsopoulous; Marketa Zvelebil; Laurence H Pearl; Frances M G Pearl
Journal:  Nucleic Acids Res       Date:  2008-11-05       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.